Chemotherapy-induced Necrosis in Ewing Sarcoma

Status Completed

Clinical Trial Summary

This is single institution cases series review of histological and clinical data

Clinical Trial Description

Investigators will retrieve from the database of the Rizzoli institute all the cases with a histological diagnosis of Ewing sarcoma from 01 Jan 1982 to 31 Dic 2012 ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03968471
Study type	Observational
Source	Istituto Ortopedico Rizzoli
Contact
Status	Completed
Phase
Start date	May 13, 2019
Completion date	January 15, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06068075` - Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD	N/A
Completed	`NCT01825902` - 18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma	Early Phase 1
Completed	`NCT00618813` - Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors	N/A
Withdrawn	`NCT05116800` - Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma	Phase 2
Recruiting	`NCT04845893` - Observational Study on Skeletal Ewing's Sarcoma
Withdrawn	`NCT01795430` - Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma	N/A
Recruiting	`NCT05033288` - Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
Completed	`NCT00674193` - Evaluating Dactinomycin and Vincristine in Young Patients With Cancer	N/A
Completed	`NCT00516295` - Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma	Phase 2
Completed	`NCT05024253` - Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements.	Phase 3
Recruiting	`NCT05395741` - Regorafenib in Patients With Refractory Primary Bone Tumors	Phase 1/Phase 2